These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1555626)

  • 1. Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome.
    Shimizu W; Ohe T; Kurita T; Takaki H; Aihara N; Kamakura S; Matsuhisa M; Shimomura K
    Eur Heart J; 1992 Feb; 13(2):261-8. PubMed ID: 1555626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.
    Spurrell RA; Thorburn CW; Camm J; Sowton E; Deuchar DC
    Br Heart J; 1975 Aug; 37(8):861-7. PubMed ID: 53057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.
    Kerr CR; Prystowsky EN; Smith WM; Cook L; Gallagher JJ
    Circulation; 1982 May; 65(5):869-78. PubMed ID: 6804107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome.
    Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T
    Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transesophageal versus intracardiac atrial stimulation in assessing anterograde conduction properties of the accessory pathway in Wolff-Parkinson-White syndrome.
    Favale S; Minafra F; Massari V; Tritto M; Rizzon P
    Int J Cardiol; 1991 Feb; 30(2):209-14. PubMed ID: 2010244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
    Harper RW; Whitford E; Middlebrook K; Federman J; Anderson S; Pitt A
    Am J Cardiol; 1982 Dec; 50(6):1323-30. PubMed ID: 7148709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
    Swerdlow CD; Peterson J; Liem LB
    Am J Cardiol; 1988 Jul; 62(1):78-82. PubMed ID: 2898208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of mexiletine in the Wolff-Parkinson-White syndrome].
    Touboul P; Gressard A; Kirkorian G; Atallah G
    Arch Mal Coeur Vaiss; 1981 Nov; 74(11):1315-23. PubMed ID: 6797370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation.
    Bennett DH
    Chest; 1978 Dec; 74(6):624-8. PubMed ID: 738119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of atropine and isoproterenol on tachycardia induction in asymptomatic patients with Wolff-Parkinson-White electrocardiographic pattern.
    Kim YH; Leitch JW; Klein GJ; Yee R; Leather RA
    Can J Cardiol; 1992 Sep; 8(7):716-20. PubMed ID: 1422992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiological effects of intravenous disopyramide phosphate on the Wolff-Parkinson-White syndrome.
    Tajima T; Dohi Y
    Pacing Clin Electrophysiol; 1982 Sep; 5(5):741-7. PubMed ID: 6182545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of the anti-arrhythmia agent ethmozin on the refractory period of the accessory pathway in Wolff-Parkinson-White syndrome].
    Rakovec P; Kenda MF
    Wien Med Wochenschr; 1986 Feb; 136(3):65-6. PubMed ID: 3515775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation.
    Kappenberger LJ; Fromer MA; Steinbrunn W; Shenasa M
    Am J Cardiol; 1984 Aug; 54(3):330-5. PubMed ID: 6465013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of isoproterenol on the anterograde refractory period of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
    Wellens HJ; Brugada P; Roy D; Weiss J; Bär FW
    Am J Cardiol; 1982 Jul; 50(1):180-4. PubMed ID: 7090999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conduction over an isthmus of atrial myocardium in vivo: a possible model of Wolff-Parkinson-White syndrome.
    Inoue H; Zipes DP
    Circulation; 1987 Sep; 76(3):637-47. PubMed ID: 3621524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of exercise on the permeability of accessory pathways and supraventricular arrhythmia in Wolff-Parkinson-White syndrome].
    Mabo P; Kermarrec A; Gras D; Paillard F; Bédossa M; Daubert C
    Arch Mal Coeur Vaiss; 1992 Oct; 85(10):1443-8. PubMed ID: 1297293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome.
    Fujimura O; Klein GJ; Sharma AD; Yee R; Szabo T
    J Am Coll Cardiol; 1989 Apr; 13(5):1133-7. PubMed ID: 2926064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of atrial fibrillation with mexiletine in Wolff-Parkinson-White syndrome].
    Róna G
    Z Gesamte Inn Med; 1986 Jun; 41(12):355-8. PubMed ID: 3765734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Wolff-Parkinson-White syndrome. Value of transesophageal atrial stimulation coupled with exercise test for the study of anterograde conduction in the accessory pathway].
    Cebron JP; Le Marec H; Victor J; Chevallier JC; Borgat C; Godin JF
    Arch Mal Coeur Vaiss; 1989 Feb; 82(2):159-66. PubMed ID: 2500076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of isoproterenol on accessory pathway conduction in intermittent or concealed Wolff-Parkinson-White syndrome.
    Yamamoto T; Yeh SJ; Lin FC; Wu DL
    Am J Cardiol; 1990 Jun; 65(22):1438-42. PubMed ID: 2353648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.